Clinical Trial Update: Netupitant and Palonosetron Hydrochloride in Preventing Chemotherapy Induced Nausea and Vomiting in Patients With Cancer Undergoing BEAM Conditioning Regimen Before Stem Cell Transplant [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating netupitant and palonosetron hydrochloride to prevent chemotherapy-induced nausea and vomiting in cancer patients undergoing BEAM condit…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Malignant Neoplasm of Unspecified Site

Drugs mentioned

• Netupitant and Palonosetron Hydrochloride (netupitant and palonosetron)

Snippet

Sponsor: OHSU Knight Cancer Institute | Conditions: Malignant Neoplasm | Phase 2 | Status: COMPLETED | Results posted: 2021-06-03